The Food and Drug Administration has issued a nationwide recall for specific lots of dabigatran etexilate capsules. This medication, a common prescription blood thinner used to prevent strokes and blood clots, failed necessary impurity and degradation testing during quality assessments. The recall applies to 75-milligram and 150-milligram capsules manufactured by Alkem Laboratories Ltd. and distributed by Major Pharmaceuticals.
Patients currently prescribed this medication should examine their packaging immediately to determine if their supply is affected. The impacted lots include 150 mg 60-count packs with lot number 25141583, 75 mg 60-count packs with lot number 25141585, and 75 mg 30-count packs with lot number 25141586. All these specific items carry an expiration date of April 30, 2027.
It is important to manage this situation correctly. You should contact your healthcare provider or pharmacist if you identify that your medication is part of this recall. Do not stop taking your prescribed treatment unless your doctor tells you to do so, as abrupt cessation of blood thinners can create significant health risks. Medical professionals can provide direct guidance on replacement options or verification of your specific supply.